GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cotinga Pharmaceuticals Inc (OTCPK:COTQF) » Definitions » Shiller PE Ratio

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Shiller PE Ratio : (As of Jun. 22, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Cotinga Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cotinga Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Cotinga Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cotinga Pharmaceuticals Shiller PE Ratio Chart

Cotinga Pharmaceuticals Annual Data
Trend Apr10 Apr11 Apr12 Apr13 Apr14 Apr15 Apr16 Apr17 Apr18 Apr19
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cotinga Pharmaceuticals Quarterly Data
Apr15 Jul15 Oct15 Jan16 Apr16 Jul16 Oct16 Jan17 Apr17 Jul17 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cotinga Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Cotinga Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cotinga Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cotinga Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cotinga Pharmaceuticals's Shiller PE Ratio falls into.



Cotinga Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Cotinga Pharmaceuticals's E10 for the quarter that ended in Jan. 2020 is calculated as:

For example, Cotinga Pharmaceuticals's adjusted earnings per share data for the three months ended in Jan. 2020 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jan. 2020 (Change)*Current CPI (Jan. 2020)
=-0.015/108.0853*108.0853
=-0.015

Current CPI (Jan. 2020) = 108.0853.

Cotinga Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201004 -0.199 91.651 -0.235
201007 -0.096 92.283 -0.112
201010 -0.098 92.757 -0.114
201101 -0.101 93.074 -0.117
201104 -0.104 94.654 -0.119
201107 -0.105 94.812 -0.120
201110 -0.098 95.444 -0.111
201201 -0.099 95.365 -0.112
201204 -0.101 96.550 -0.113
201207 -0.099 95.997 -0.111
201210 -0.101 96.550 -0.113
201301 -0.101 95.839 -0.114
201304 0.000 96.945 0.000
201307 -0.096 97.261 -0.107
201310 -0.096 97.182 -0.107
201401 -0.091 97.261 -0.101
201404 -0.091 98.920 -0.099
201407 -0.093 99.315 -0.101
201410 -0.089 99.473 -0.097
201501 -0.082 98.209 -0.090
201504 -0.081 99.710 -0.088
201507 -0.078 100.579 -0.084
201510 -0.076 100.500 -0.082
201601 -0.070 100.184 -0.076
201604 -0.148 101.370 -0.158
201607 -0.123 101.844 -0.131
201610 -0.038 102.002 -0.040
201701 -0.061 102.318 -0.064
201704 -0.097 103.029 -0.102
201707 -0.016 103.029 -0.017
201710 -0.087 103.424 -0.091
201801 -0.064 104.056 -0.066
201804 -0.079 105.320 -0.081
201807 -0.030 106.110 -0.031
201810 -0.015 105.952 -0.015
201901 -0.008 105.557 -0.008
201904 -0.030 107.453 -0.030
201907 -0.015 108.243 -0.015
201910 -0.015 107.927 -0.015
202001 -0.015 108.085 -0.015

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cotinga Pharmaceuticals  (OTCPK:COTQF) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Cotinga Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Cotinga Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C1P1
Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Headlines

From GuruFocus

Cotinga Pharmacueticals Announces Closing of Unit Offering

By GlobeNewswire GlobeNewswire 05-22-2019